Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $205.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price hoisted by Morgan Stanley from $185.00 to $205.00 in a report published on Monday morning, Marketbeat reports. The brokerage currently has an overweight rating on the specialty pharmaceutical company’s stock.

A number of other brokerages have also recently issued reports on JAZZ. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Wells Fargo & Company set a $170.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 22nd. Royal Bank Of Canada increased their price target on shares of Jazz Pharmaceuticals from $151.00 to $155.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Wall Street Zen raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 8th. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $195.07.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $176.08 on Monday. The firm has a market capitalization of $10.70 billion, a PE ratio of -26.16, a PEG ratio of 8.49 and a beta of 0.29. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals has a 1-year low of $95.49 and a 1-year high of $182.99. The business’s 50 day moving average is $136.90 and its 200-day moving average is $121.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, beating analysts’ consensus estimates of $5.87 by $2.26. The business had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.Jazz Pharmaceuticals’s revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the company posted $6.54 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. Sell-side analysts predict that Jazz Pharmaceuticals will post 16.96 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Robert Iannone sold 7,159 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $168.26, for a total value of $1,204,573.34. Following the transaction, the executive vice president directly owned 72,628 shares of the company’s stock, valued at $12,220,387.28. The trade was a 8.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the sale, the director owned 429,973 shares in the company, valued at approximately $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 18,659 shares of company stock valued at $2,729,853 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 9.0% during the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 81 shares in the last quarter. Tectonic Advisors LLC lifted its stake in Jazz Pharmaceuticals by 1.5% in the 3rd quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock valued at $742,000 after acquiring an additional 82 shares in the last quarter. Teacher Retirement System of Texas boosted its position in Jazz Pharmaceuticals by 0.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock worth $1,651,000 after acquiring an additional 90 shares during the last quarter. Fairbanks Capital Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 0.4% during the 3rd quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock worth $3,298,000 after acquiring an additional 94 shares in the last quarter. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its stake in shares of Jazz Pharmaceuticals by 8.7% during the 2nd quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,250 shares of the specialty pharmaceutical company’s stock worth $133,000 after acquiring an additional 100 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.